Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
NCT01815528
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
2
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Epithelial Ovarian Cancer
Interventions
DRUG:
Catumaxomab
Sponsor
JSehouli